XenoPort, Inc. (Nasdaq: XNPT) announced today positive preliminary results from a Phase 2 clinical trial of arbaclofen placarbil, also known ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE